Corbus Pharmaceuticals Holdings, Inc.
CRBP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.33 | -0.01 | 0.12 | 0.07 |
| FCF Yield | -19.65% | -25.34% | -7.61% | -5.62% |
| EV / EBITDA | -3.81 | -2.88 | -13.83 | -17.51 |
| Quality | ||||
| ROIC | -16.63% | -15.22% | -8.65% | -9.96% |
| Gross Margin | 0.00% | 0.00% | -20.76% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.94 | 0.97 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -1.08% | -50.07% | 21.52% | -55.90% |
| Safety | ||||
| Net Debt / EBITDA | 1.00 | 0.95 | 1.49 | 1.19 |
| Interest Coverage | 0.00 | 0.00 | -19.04 | -40.70 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,589.20 | -3,661.20 | -2,950.27 | -1,299.15 |